ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
UCB and Biogen presented five posters at ACR Convergence 2026 showing dapirolizumab pegol outperformed placebo plus standard of care across novel and sustained-response endpoints in the Phase 3 PHOENYCS GO lupus study. In the first application of the new TRM-SLE measure to the data, 61.2% of DZP patients achieved TRM-SLE-50 response versus 43.2% on placebo, and 52.5% achieved TRM-SLE-100 versus 36.8%, through Week 48. Separate post-hoc analyses showed roughly double the rates of sustained low disease activity (24.0% vs 10.3%) and higher sustained remission (11.5% vs 4.7%) versus placebo, all nominally significant.
Key figures
- Drug Name
- dapirolizumab pegol (DZP)
- Phase Of Trial
- Phase 3
- Bicla
- 50% (103/208) vs 35% (37/107); p=0.011
- Sri 4
- 60% (125/208) vs 41% (44/107)
- Trm sle 50
- 61.2% vs 43.2% (DZP+SOC vs placebo+SOC)
- Trm sle 100
- 52.5% vs 36.8%
- Sustained doris
- 11.5% vs 4.7%; nominal p=0.0253
- Sustained lldas
- 24.0% vs 10.3%; nominal p=0.0012
- Sustained lldas 5
- 19.2% vs 5.6%; nominal p=0.0002
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.